Abstract:Summary Background Broad-capture proteomic technologies have the potential to improve disease prediction, enabling targeted prevention and management, but studies have so far been limited to very few selected diseases and have not evaluated predictive performance across multiple conditions. We aimed to evaluate the potential of serum proteins to improve risk prediction over and above health-derived information and polygenic risk scores across a diverse set of 24 outcomes. Methods We designed multiple case-cohorts nested in the EPIC-Norfolk prospective study, from participants with available serum samples and genome-wide genotype data, with more than 32 974 person-years of follow-up. Participants were middle-aged individuals (aged 40–79 years at baseline) of European ancestry who were recruited from the general population of Norfolk, England, between March, 1993 and December, 1997. We selected participants who developed one of ten less common diseases within 10 years of follow-up; we also subsampled a randomly drawn control subcohort, which also served to investigate 14 more common outcomes (n>70), including all-cause premature mortality (death before the age of 75 years; case numbers 71–437; controls 608–1556). Individuals were excluded from the current study owing to failed genotyping or proteomic quality control, relatedness, or missing information on age, sex, BMI, or smoking status. We used a machine learning framework to derive sparse predictive protein models for the onset of the the 23 individual diseases and all-cause premature mortality, and to derive a single common sparse multimorbidity signature that was predictive across multiple diseases from 2923 serum proteins. Findings Participants who developed one of ten less common diseases within 10 years of follow-up included 482 women and 507 men, with a mean age at baseline of 64·56 years (8·08). The random subcohort included 990 women and 769 men, with a mean age of 58·79 years (9·31). As few as five proteins alone outperformed polygenic risk scores for 17 of 23 outcomes (median dfference in concordance index [C-index] 0·13 [0·10–0·17]) and improved predictive performance when added over basic patient-derived information models for seven outcomes, achieving a median C-index of 0·82 (IQR 0·77–0·82). This included diseases with poor prognosis such as lung cancer (C-index 0·85 [+/− cross-validation error 0·83–0·87]), for which we identified unreported biomarkers such as C-X-C motif chemokine ligand 17. A sparse multimorbidity signature of ten proteins improved prediction across seven outcomes over patient-derived information models, achieving performances (median C-index 0·81 [IQR 0·80–0·82]) similar to those of disease-specific signatures. Interpretation We show the value of broad-capture proteomic biomarker discovery studies across multiple diseases of diverse causes, pointing to those that might benefit the most from proteomic approaches, and the potential to derive common sparse biomarker panels for prediction of multiple diseases at once. This framework could enable follow-up studies to explore the generalisability of proteomic models and to benchmark these against clinical assays, which are required to understand the translational potential of these findings. Funding Medical Research Council, Health Data Research UK, UK Research and Innovation–National Institute for Health and Care Research, Cancer Research UK, and Wellcome Trust.

Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study

A Three-Stage Search Strategy Combining Database Reduction and Retention Time Filtering to Improve the Sensitivity of Low-Input and Single-Cell Proteomic Analysis.

Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms

Optimizing Sample Size for Supervised Machine Learning with Bulk Transcriptomic Sequencing: A Learning Curve Approach

A flexible framework for minimal biomarker signature discovery from clinical omics studies without library size normalisation

Simulated linear test applied to quantitative proteomics

Statistical development and assessment of summary measures to account for isotopic clustering of Fourier transform mass spectrometry data in clinical diagnostic studies

Quantitative Comparison of Statistical Methods for Analyzing Human Metabolomics Data

Machine learning in rare disease

Machine learning strategies to tackle data challenges in mass spectrometry-based proteomics

Robust, Precise, and Deep Proteome Profiling Using a Small Mass Range and Narrow Window Data-Independent-Acquisition Scheme

Proteomic prediction of diverse incident diseases: a machine learning-guided biomarker discovery study using data from a prospective cohort study

Large scale proteomic studies create novel privacy considerations

Expanding the coverage of spatial proteomics: a machine learning approach

Interpretable Machine Learning Leverages Proteomics to Improve Cardiovascular Disease Risk Prediction and Biomarker Identification

The Effects of Sample Size on Omics Study: from the Perspective of Robustness and Diagnostic Accuracy

Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning

A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies

Improving the success rate of proteome analysis by modeling protein-abundance distributions and experimental designs

Simple and robust high-throughput serum proteomics workflow with low-microflow LC–MS/MS

Proteomic signatures improve risk prediction for common and rare diseases